Global Viral Clearance Market was valued at USD 493.0 Million in 2021, and it is expected to reach a value of USD 1,401.7 Million by 2028, at a CAGR of 16.1% over the forecast period (2022 – 2028).
Viral clearance is defined as the removal of viral particles and TSE (Transmissible spongiform encephalopathy) agents from the manufacturing process of development for monoclonal antibodies, recombinant proteins and glycoproteins, tissue, blood-derived products, and medical devices as these products are at risk from bacteria, chemical impurities, fungi, and from viruses. Viral contamination can affect cell culture processes, raw materials, bioreactor contamination, and downstream processing which in turn creates demand for viral safety practices along with the implementation of the virus clearance process into the manufacturing process thus, viral clearance plays a vital role here. Increasing investments in the field of pharmaceutical and biotechnology and rising demand for vaccines and other biotherapeutic agents are driving the market for global viral clearance market in the upcoming years.
Get more info about this report at : https://skyquestt.com/report/viral-clearance-market
Global Viral Clearance Market Segmental Analysis
Global Viral Clearance Market segmentation is based on method, application, end-user, and region. Based on the method, the market is segmented into the Viral Removal Method, Viral Inactivation Method, and Viral Detection Method. Based on Application, the market is segmented into Recombinant Proteins, Blood and Blood Products, Vaccines, and Others. Based on end-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others. Based on Region the market is segmented into North America, Europe, Asia-Pacific, Latin America, and MEA.
- By Type:Viral Removal Method, Viral Inactivation Method, Viral Detection Method
- By Application:Recombinant Proteins, Blood, Blood Products, Vaccines, Others
- By End User:Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Others
Top Players Company Profiles
- Merck KgaA (Germany)
- Charles River (US)
- WuXi Biologics (China)
- Texcell (France)
- Vironova (Sweden)
- Kedrion (Italy)
- Clean Cells (France)
- Virusure GmbH (Austria)
- Sartorius AG (Germany)
- BSL Bio service (Germany)
Get free sample pdf report copy at : https://skyquestt.com/sample-request/viral-clearance-market
Recent Development
- In June 2022, Asahi Kasei Medical is expanding into the CDMO business with the acquisition of Bay Area biologics maker Bionova Scientific for an undisclosed price. Like many in the industry, Japan-based Asahi Kasei has been on an expansion tear during the past few years. It purchased Austrian viral safety testing services provider Virusure Forschung und Entwicklung in 2019 and last year snapped up U.S-based mycoplasma testing services company Bionique Testing Labs.
- In August 2021, WuXi Biologics announced that just 13 months after receiving its first GMP certificate, it has also received European Medicines Agency (EMA) GMP certificate for Biosafety testing center in Suzhou. This certificate demonstrates WuXi Biologics’ compliance with international cGMP safety assessment standards and regulatory guidelines.
About Us:
SkyQuest Technology Group is a Global Market Intelligence, Innovation Management & Commercialization organization that connects innovation to new markets, networks & collaborators for achieving Sustainable Development Goals.
Contact Us:
SkyQuest Technology Consulting Pvt. Ltd.
1 Apache Way,
Westford,
Massachusetts 01886
USA (+1) 617-230-0741
Email- info@skyquestt.com
Website: https://www.skyquestt.com/
